What Does the Future Hold for Coronary Artery Revascularization?
Unless otherwise noted, speakers have nothing to disclose.
Moderators
Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Duravena: Consultant (Ongoing); Potrero Med: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); ReValve Med: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Faisal Bakaeen, MD
Presentations
- New Guidelines, New Techniques, and the Future of CABG
Marc Ruel, MD, MPH
Disclosure: Medtronic: Proctor (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Total arterial multivessel minimally invasive coronary bypass surgery via left lateral mini-thoracotomy: 5 year outcomes
Piroze M. Davierwala, MD
- Coronary Revascularization: A Cardiologist's Perspective
Michael Farkouh, MD, MSc
Disclosure: Amgen: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otitopic: Consultant (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
- Conduit Choice
Mario FL Gaudino, MD, PhD, MSCE
- Panel Discussion
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Price
Unless otherwise noted, speakers have nothing to disclose.
Moderators
Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Duravena: Consultant (Ongoing); Potrero Med: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); ReValve Med: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Faisal Bakaeen, MD
Presentations
- New Guidelines, New Techniques, and the Future of CABG
Marc Ruel, MD, MPH
Disclosure: Medtronic: Proctor (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Total arterial multivessel minimally invasive coronary bypass surgery via left lateral mini-thoracotomy: 5 year outcomes
Piroze M. Davierwala, MD
- Coronary Revascularization: A Cardiologist's Perspective
Michael Farkouh, MD, MSc
Disclosure: Amgen: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otitopic: Consultant (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
- Conduit Choice
Mario FL Gaudino, MD, PhD, MSCE
- Panel Discussion